Inficure AB – in vivo validation of fibrotic drug candidates
InfiCure Bio offered advanced drug validation services for pharmaceutical companies developing drugs against fibrosis – or scar tissue formation in organs. The shortage of existing model systems that reflect human fibrotic disease conditions made it an attractive CRO-service for pharmaceutical developers. Due to the pandemic, the company experienced a significant decline in clients, ultimately leading to its closure in the fall of 2023.
